Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Trutino Biosciences Inc. has 1 pending office action in Biotechnology & Pharmaceuticals. Its record shows 1 distinct examiner and 1 distinct art unit, so the available prosecution activity is directed through a single examiner and examination group.
PATTERSON, SARAH COOPER is identified as the busiest examiner and handles the pending action. A response strategy can be tailored to that examiner’s treatment of the application without needing to coordinate across multiple examination channels.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| PATTERSON, SARAH COOPER | 1 | 56.1% | +51.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17629744 | IL-2 CYTOKINE PRODRUGS COMPRISING A CLEAVABLE LINKER | PATTERSON, SARAH COOPER | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17629744 | IL-2 CYTOKINE PRODRUGS COMPRISING A CLEAVABLE LINKER | PATTERSON, SARAH COOPER | — |
| Art Unit | Apps |
|---|---|
| 1675 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17629744 | IL-2 CYTOKINE PRODRUGS COMPRISING A CLEAVABLE LINKER | PATTERSON, SARAH COOPER | 1675 | §103§112 | Final Rejection | — | Pending | Jan 24, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialTrutino Biosciences Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Sarah Cooper Patterson has the most, with 1 of Trutino Biosciences Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
